Table S5. Clinical characteristics of patients with versus without SAD

| Clinical variable | Patients with SAD (n=63) | Patients without SAD (n= 89) | p-value |
|-------------------|--------------------------|-----------------------------|---------|
| Age [yrs]         | 58.9 (48.90, 66.9)       | 50.9 (42.7, 57.4)           | 0.002   |
| BMI [Kg/m²]       | 27.4 (24.5, 31.3)        | 27.0 (24.38, 30.46)         | 0.367   |
| Adult onset asthma, n | 42 (67%)             | 59 (66%)                    | 0.992   |
| Female, n         | 28 (44%)                 | 56 (63%)                    | 0.036   |
| Current or former smokers ≥10PY, n | 21 (33%)       | 18 (20%)                    | 0.102   |

Atopy, blood and sputum differential counts

| Clinical variable | Patients with SAD (n=63) | Patients without SAD (n= 89) | p-value |
|-------------------|--------------------------|-----------------------------|---------|
| Blood eosinophil granulocytes [1000/µl] | 0.29 (0.16, 0.58) | 0.30 (0.14, 0.48) | 1       |
| Blood neutrophil granulocytes [1000/µl] | 4.56 (3.34, 6.71) | 4.25 (3.37, 5.31) | 0.349   |
| Sputum eosinophil granulocytes [%] | 3.20 (0.80, 15.70) | 1.35 (0.33, 4.38) | 0.031   |
| Sputum neutrophil granulocytes [%] | 56.70 (33.30, 76.10) | 55.10 (30.90, 69.80) | 0.548   |

Asthma severity

| Clinical variable | Patients with SAD (n=63) | Patients without SAD (n= 89) | p-value |
|-------------------|--------------------------|-----------------------------|---------|
| Mild-moderate asthma, n | 27 (43%)             | 64 (72%)                    | 0.001   |
| Severe asthma, n | 36 (57%)                 | 25 (28%)                    | 0.001   |
| Asthma control questionnaire (ACQ) | 2.0 (1.0, 3.3)     | 1.1 (0.6, 2.3)              | <0.001  |
| Asthma quality of life questionnaire (AQLQ) | 4.94 (4.02, 5.97) | 5.66 (4.46, 6.28)          | 0.046   |

GINA control status

| Clinical variable | Patients with SAD (n=63) | Patients without SAD (n= 89) | p-value |
|-------------------|--------------------------|-----------------------------|---------|
| Controlled, n | 12 (19%)                 | 36 (41%)                    | 0.004   |
| Partly controlled, n | 18 (29%)              | 28 (32%)                    | 0.004   |
| Uncontrolled, n | 33 (52%)                 | 25 (28%)                    | 0.004   |

Lung function

| Clinical variable | Patients with SAD (n=63) | Patients without SAD (n= 89) | p-value |
|-------------------|--------------------------|-----------------------------|---------|
| Patients with R5-R20 > ULN | 63 (100%)   | 0 (0%)                      | <0.001  |
| Patients with AX > ULN | 56 (90%)     | 14 (16%)                    | <0.001  |
| FEV₁ [z-score] | -2.43 (-3.17, -1.70)     | -0.98 (-1.69, -0.06)        | <0.001  |
| FEV₁/FVC [z-score] | -2.67 (-3.52, -1.74) | -1.26 (-1.89, -0.55)        | <0.001  |
| FEF₂₅-₇₅ [z-score] | -2.72 (-3.15, -1.58) | -1.24 (-1.91, -0.47)        | <0.001  |
| FeNO [ppb] | 30.0 (16.5, 44.5)        | 25.5 (15.0, 41.8)           | 0.557   |

Medication

| Clinical variable | Patients with SAD (n=63) | Patients without SAD (n= 89) | p-value |
|-------------------|--------------------------|-----------------------------|---------|
| ICS (Fluticasone-equivalent) [µg/d] | 670 (510)     | 430 (440)                    | 0.001   |
| LTRA, n | 11 (18%)                 | 13 (15%)                    | 0.803   |
| LABA, n | 56 (89%)                 | 71 (80%)                    | 0.204   |
|                  | Median (25%, 75% IQR) | Number (%)  | p-value |
|------------------|------------------------|-------------|---------|
| LAMA, n          | 21 (33%)               | 14 (16%)    | 0.019   |
| Oral corticosteroids, n | 20 (32%)               | 16 (18%)    | 0.076   |
| Omalizumab, n    | 2 (3%)                 | 3 (3%)      | 1       |
| Mepolizumab, n   | 1 (2%)                 | 1 (1%)      | 1       |

**TABLE S5. Clinical characteristics of patients with versus without SAD.** Data is presented as median (25%, 75% IQR), and number (%). Yrs, years, n, number of patients; BMI, Body Mass Index; PY, pack-years; GINA, Global Initiative for Asthma; ACQ, Asthma Control Questionnaire; AQLQ, Asthma Quality Of Life Questionnaire; R5–R20, resistance at 5 Hz – resistance at 20 Hz [kPa/l/s]; AX, reactance area [kPa/l/s]; ULN, upper limit of normal; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; FEV1/FVC, FEV1 as % of FVC; FEF25-75, forced expiratory flow at 25% - 75% of FVC; FeNO, fractional exhaled nitric oxide; ppb, parts per billion; LTRA, leukotriene antagonist; LABA, long-acting β2 agonist; LAMA, long-acting muscarinic antagonist.